BioMed X Launched Neuroscience Research in New Haven
The research team will study brain circuit mechanisms underlying anhedonia.
Updated on Sept. 29, 2026 in Alzheimer’s
Live Poll
Do you trust that pharmaceutical industry partnerships prioritize effective treatments for patients?
BioMed X has launched a new neuroscience research team in New Haven to investigate the mechanisms of anhedonia. The project aims to develop model systems with human translational value to improve treatment efficacy.
Why it matters
Current medications for anhedonia often lack efficacy because the underlying brain circuit mechanisms remain poorly understood. This research seeks to identify new biomarkers to bridge this critical knowledge gap in mental health treatment.
This research is the first team-based project located at BioLabs in New Haven. It is the third research project initiated under the long-standing partnership between BioMed X and AbbVie.
The players
BioMed X
This is a research institute that partners with industry leaders to drive innovation in biomedical sciences.
AbbVie
This is a global biopharmaceutical company focused on developing advanced therapies for complex health conditions.
Dr. Kevin Michael Keary III
He is the lead scientist responsible for directing the newly formed research team in New Haven.
The details
The research team will use human translational model systems to investigate brain circuit mechanisms that drive anhedonia. By focusing on these circuits, the team intends to uncover reliable biomarkers that could lead to more effective future therapies.
Timeline
The collaboration between BioMed X and AbbVie began in 2015.
The partners launched their first U.S.-based project in 2023.
BioMed X announced the new research team on September 29, 2026.
The Big Picture
The establishment of this research team follows the strategic framework set by the BioMed X and AbbVie collaborative research partnership. This launch marks an expansion of the joint efforts that began in Heidelberg to broaden the scope of their neuroscience innovation.
This research does not provide immediate treatment options for patients but aims to eventually deliver more effective medication for those experiencing anhedonia. It represents a long-term investment in understanding the biology behind mental health symptoms.
The takeaway
Advancing the understanding of brain circuit mechanisms is essential for developing next-generation psychiatric treatments. Researchers hope that defining clear biomarkers will provide a foundation for future drug discovery efforts.
Further reading
For more information on similar brain health studies, visit our Alzheimer’s section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust that pharmaceutical industry partnerships prioritize effective treatments for patients?
